Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Biocartis Group NV's EV-to-EBIT or its related term are showing as below:
LTS:0R72's EV-to-EBIT is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 24.54 * Ranked among companies with meaningful EV-to-EBIT only.
Biocartis Group NV (LTS:0R72) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Biocartis Group NV's Enterprise Value for the quarter that ended in Jun. 2023 was €161.75 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocartis Group NV's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-51.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocartis Group NV EV-to-EBIT Related Terms
Biocartis Group NV EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Biocartis Group NV's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Biocartis Group NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocartis Group NV EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biocartis Group NV's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Biocartis Group NV's EV-to-EBIT falls into.
Biocartis Group NV's current Enterprise Value is €154.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocartis Group NV's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-51.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocartis Group NV (LTS:0R72) has a EV-to-EBIT of -2.97 as of Aug. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biocartis Group NV and its competitors.
Is Biocartis Group NV's EV-to-EBIT too high?
Biocartis Group NV's current EV-to-EBIT is -2.97. Overall, Biocartis Group NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Biocartis Group NV's EV-to-EBIT compare to TMO and DHR?
Biocartis Group NV's EV-to-EBIT of -2.97 can be compared against companies in the Medical Diagnostics & Research industry. The industry median EV-to-EBIT is 24.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 24.54, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biocartis Group NV and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 24.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocartis Group NV's current EV-to-EBIT is -2.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocartis Group NV stock overvalued right now?
Biocartis Group NV (LTS:0R72) has a current EV-to-EBIT of -2.97. The current EV-to-EBIT is -2.97. Biocartis Group NV's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Biocartis Group NV (LTS:0R72), the current EV-to-EBIT is -2.97 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an Meet Idylla molecular diagnostic system for oncology and infectious disease segments.
14GF Score
Get the complete analysis for LTS:0R72
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R72 has been successfully added to your 
